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Endometrial cancer is the most common gynecological malignancy, with more than 280,000 cases occurring annually
worldwide. Although previous studies have identified important common somatic mutations in endometrial cancer, they
have primarily focused on a small set of known cancer genes and have thus provided a limited view of the molecular basis
underlying this disease. Here we have developed an integrated systems-biology approach to identifying novel cancer
genes contributing to endometrial tumorigenesis. We first performed whole-exome sequencing on 13 endometrial cancers
and matched normal samples, systematically identifying somatic alterations with high precision and sensitivity. We then
combined bioinformatics prioritization with high-throughput screening (including both shRNA-mediated knockdown
and expression of wild-type and mutant constructs) in a highly sensitive cell viability assay. Our results revealed 12
potential driver cancer genes including 10 tumor-suppressor candidates (ARID1A, INHBA, KMO, TTLL5, GRM8, IGFBP3, AKTIP,
PHKA2, TRPS1, and WNT11) and two oncogene candidates (ERBB3 and RPS6KC1). The results in the ‘‘sensor’’ cell line were
recapitulated by siRNA-mediated knockdown in endometrial cancer cell lines. Focusing on ARID1A, we integratedmutation
profiles with functional proteomics in 222 endometrial cancer samples, demonstrating that ARID1A mutations frequently
co-occur with mutations in the phosphatidylinositol 3-kinase (PI3K) pathway and are associated with PI3K pathway ac-
tivation. siRNA knockdown in endometrial cancer cell lines increased AKT phosphorylation supporting ARID1A as a novel
regulator of PI3K pathway activity. Our study presents the first unbiased view of somatic coding mutations in endometrial
cancer and provides functional evidence for diverse driver genes and mutations in this disease.
[Supplemental material is available for this article.]
Endometrial cancer is the most common gynecological malignancy
and the fourth most common cancer among women in Western
countries, with more than 280,000 cases occurring annually
worldwide (Ferlay et al. 2010). Although the prognosis is favorable
for patients identified with early-stage disease, the outcomes for
patients with metastatic or recurrent endometrial cancer remain
abysmal, with median survival of <1 yr. For effective cancer pre-
vention and treatment, it is necessary to identify critical genetic
changes that initiate endometrial cancer and contribute to its
progression. Over the last decade, multiple groups have identified
common somatic mutations of several important genes in endo-
metrial cancer (Dedes et al. 2011). For example, PIK3CAmutations
occur in ;30% of endometrial cancers, with the mutation fre-
quency varying according to histological grade (Oda et al. 2005;
Velasco et al. 2006; Catasus et al. 2008; Miyake et al. 2008; Hayes
et al. 2009; Cheung et al. 2011). PTEN, a major negative regulator
of the phosphatidylinositol 3-kinase (PI3K) pathway, is frequently
mutated in endometrial tumors (Risinger et al. 1998; Mutter et al.
2000; Sun et al. 2001; Salvesen et al. 2004). Other cancer genes
such as TP53,KRAS,AKT, andCTNNB1 are also frequentlymutated
in this disease (Lax et al. 2000; Schlosshauer et al. 2000; Moreno-
Bueno et al. 2002; Stefansson et al. 2004; Byron et al. 2008; Jia et al.
2008; Catasus et al. 2009; Shoji et al. 2009). More recently, we have
demonstrated that PI3K pathway aberrations occur in >80% of
endometrial cancers, oftenwith co-mutations ofmultiple pathway
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members (Cheung et al. 2011). Although these studies provide
important insights into the molecular basis of endometrial cancer,
they have primarily focused on a limited set of well-known cancer
genes. To date, a comprehensive view of the mutation spectrum in
this disease has not been achieved.
Recent advances in next-generation sequencing technology
have enabled the unprecedented characterization of a full spec-
trum of somatic alterations in cancer genomes (Mardis 2011). In
particular, through target enrichment, whole-exome sequencing
represents a cost-effective strategy to identify mutations in pro-
tein-coding exons in the human genome. In the past several years,
this approach has been successfully applied to several human
cancers (Cancer Genome Atlas Research Network 2008, 2011;
Jones et al. 2010; Gui et al. 2011;Wang et al. 2011). Given the large
numbers of somaticmutations typically detected by this approach,
a key challenge in the downstream analysis is to distinguish
‘‘drivers’’ that functionally contribute to tumorigenesis from
‘‘passengers’’ that occur as the consequence of genomic instability.
So far, most of the published studies have characterized at most
one or two genes of interest, leaving the vast majority of mutated
genes unexplored.
Here we implemented a systems-biology approach to iden-
tify driver cancer genes in endometrial cancers. We first per-
formed whole-exome sequencing on 13 endometrial cancers
along with matched normal samples to detect somatic alter-
ations with high precision and sensitivity. For validated mutated
genes, we combined bioinformatics prioritization with high-
throughput screening of short-hairpin RNA (shRNA) and over-
expression constructs in a highly sensitive cell viability assay to
identify candidate driver cancer genes. The impact of candidate
driver genes from the initial screenwas then assessed in endometrial
cancer cell lines by small interfering RNA (siRNA) knockdown.
Finally, we focused on one candidate driver gene, ARID1A, for
mechanistic investigation. Figure 1 shows an overview of our ap-
proach. Our study thus provides an integrated approach to identi-
fying and characterizing novel cancer genes that have not been
implicated in endometrial tumorigenesis.
Results
Landscape of somatic mutations in the exomes
of endometrial cancer
To gain an unbiased view of somatic alterations that contribute to
the pathogenesis of endometrial cancer, we performed whole-
exome sequencing of 14 endometrial tumor samples (one tumor
with an unusually high mutation frequency and low estimated
tumor content was excluded from further analysis) and matched
normal DNA samples using the SOLiD platform. Supplemental
Table 1 provides the histologic information and other clinical
characteristics of these samples. On average, we obtained 185 mil-
lion 50-nt single reads for tumor samples and 62 million reads for
normal samples (Table 1). The Agilent SureSelect capture reagent
used for enrichment targets 170,843 exons (;1.2% of the human
genome); for the targeted regions, the average coverage was 943
and 423 for tumor and normal samples, respectively. We de-
veloped a computational pipeline to detect somatic mutations by
comparing single-nucleotide variations in tumor and normal
samples (Supplemental Figs. 1, 2; Supplemental Methods). At the
depth of sequencing used and with the majority of tumors being
low grade (grade 2), we identified a mean of 89.5 somatic point
mutations (range 34–263) per tumor corresponding to an average
of 3.7 mutations per megabase (range 0.98–12.0) (Table 1). As
shown in Figure 2, the most common mutations were transitions
in the CpG context (that is, G>A/C>T), which parallels several
other cancer lineages (Ding et al. 2010; Chapman et al. 2011;
Puente et al. 2011). In addition, the tumors contained a mean of
14.2 somatic coding small insertion/deletions (indels) (Table 1;
Supplemental Table 2; Supplemental Methods).
Focusing on somaticmutations that potentially affect protein
function, across the 13 tumor samples, we identified 576 unique
nonsynonymous mutations and 24 nonsense mutations in 566
genes (Supplemental Table 2). The most perturbed biological
pathways were integrin, angiopoietin, complement system, and
PTEN signaling (Fisher exact test, P < 2.8 3 103, false discovery
rate [FDR] < 0.05, Supplemental Table 3). Based on potential bi-
ological interest, we selected 97 mutation sites for Sequenom
MassARRAY validation and obtained a true-positive rate of 81%,
leading to 69 genes with validated mutations and a prediction of
487 nonsynonymous mutations and 18 nonsense mutations in
the 13 tumors (Supplemental Table 2; Supplemental Methods). To
estimate the sensitivity of our mutation calling algorithm, we ex-
amined full-length sequences of nine genes with concurrent
Sanger sequencing and Sequenom MassARRAY detection. The es-
timated sensitivity was 80%, with false negatives occurring pri-
marily due to low coverage (Supplemental Methods). These results
indicate that the identified mutated gene set largely characterizes
the landscape of somatic coding mutations in the 13 endometrial
cancers assessed.
Novel candidate driver cancer genes revealed by Ba/F3
functional assays
Several of the validated mutated genes have previously been
shown to be targeted in endometrial cancers, including TP53,
PTEN, CTNNB1, PIK3CA, PIK3R1, and PIK3R2 (Lax et al. 2000; Sun
et al. 2001; Moreno-Bueno et al. 2002; Oda et al. 2005; Cheung
et al. 2011). We recently reported their mutation profiles in a large
collection of well-characterized endometrial tumors, demonstrat-
ing that aberrations, including frequent co-mutations, of the PI3K
pathway occur in ;80% of endometrial cancers (Cheung et al.
Figure 1. Overview of our systems-biology approach to identifying
cancer driver genes in endometrial cancer.
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2011). However, the functional roles of the remaining mutated
genes in endometrial cancer are largely unknown. To identify po-
tential driver cancer genes for further characterization, we per-
formed bioinformatics analyses and selected 30 genes using the
following criteria: (1) if the mutation in a gene is predicted to have
a high impact on the protein function by CHASM (FDR of impact
score <30%) (Carter et al. 2010) or MutationAssessor (high impact)
(Reva et al. 2011); or (2) a gene contains multiple or recurrent mu-
tations (Methods). Supplemental Table 4 provides details on selec-
tion of candidates for further analysis. We then evaluated the func-
tional impact of these selected genes inmurine Ba/F3 cells (Warmuth
et al. 2007). This cell line is amurine bonemarrow-derived pro-B-cell
line that depends on interleukin-3 (IL-3) for proliferation, but readily
becomes IL3-independent in the presence of an oncogene or onco-
genic event. Thus, the Ba/F3 cells represent a sensitive tool for
measuring the effect of an introduced perturbation on cell pro-
liferation and survival, not only for kinase
genes but also non-kinase genes (Lutz et al.
2000; Warmuth et al. 2007; Yoda et al.
2010; Cheung et al. 2011).
We first performed a ‘‘loss-of-
function’’ analysis on the 30 candidate
genes using shRNA gene silencing. As
shown in Figure 3A, compared with pa-
rental cells and cells transfected with
empty vector or nonspecific shRNAs, in-
hibiting the expression of eight genes
(INHBA, KMO, PHKA2, TTLL5, AKTIP,
IGFBP3, GRM8, and ARID1A) with two
independent shRNAs was sufficient
to promote the IL3-independent survival
of Ba/F3, compatible with these genes
having tumor-suppressor-like activity. In
contrast, the introduction of ERBB3 and
RPS6KC1 shRNAs remarkably inhibited
IL3-independent cell survival, compati-
ble with oncogene-like activity. These
observations were confirmed by at least
one of two additional independent
shRNAs in a secondary screen (data not
shown).We confirmed shRNA knockdown
efficacy by Western blotting for eight pro-
teins where appropriate antibodies were
available (Fig. 3C). Nine genes with efficient shRNA knockdown
had no effect in the Ba/F3 cells with four (NOS1AP, CDK17,
C1orf198, and PHKG1) shown in Figure 3A and Supplemental
Figure 3a. One of two shRNAs in the initial screen for two genes
(TRPS1 and WNT11) promoted IL3-independent Ba/F3 survival.
The activity was confirmed by two additional independent shRNAs
(Fig. 3B; Supplemental Fig. 3b). Significant knockdown was not
observed or antibodies were unavailable for the remaining nine
genes. Taken together, the shRNA-mediated knockdown screen
revealed 12 potential driver cancer genes including 10 tumor
suppressors and two oncogene candidates from the 30 genes
assessed in the Ba/F3 survival assay.
To complement the shRNA screen, we performed a ‘‘gain-of-
function’’ analysis on 17 out of the 30 genes by overexpressing the
wild-type or mutated gene in the Ba/F3 cells. Among the 17 genes
examined, six genes were scored positive in the Ba/F3 shRNA
Table 1. Landscape of somatic mutations in the exomes of 13 endometrial tumors
Patient ID
Tumor bases
sequenced
Normal bases
sequenced
Tumor exome
coverage
Normal exome
coverage
Callable
positions
All point
mutations
Nonsilent
mutations
Mutation rate
(per Mb)
Coding
indels
E27 9.75 3 109 4.90 3 109 93.03 55.03 30.9 3 106 91 49 2.95 15
E28 8.84 3 109 4.18 3 109 86.33 35.83 25.1 3 106 75 48 2.99 7
E35 8.75 3 109 4.60 3 109 92.03 47.43 29.0 3 106 35 19 1.21 10
E58 9.17 3 109 4.69 3 109 94.13 41.73 29.1 3 106 44 24 1.51 6
E62 9.55 3 109 2.72 3 109 99.63 18.73 21.9 3 106 263 146 12.0 52
E70 9.76 3 109 4.35 3 109 88.33 45.23 20.7 3 106 79 43 3.82 8
E82 9.22 3 109 4.01 3 109 87.13 44.83 31.2 3 106 30 13 0.96 14
E99 8.84 3 109 4.74 3 109 89.23 48.53 29.9 3 106 36 17 1.20 10
E101 9.13 3 109 4.60 3 109 95.73 52.83 31.3 3 106 34 18 1.09 14
E114 8.97 3 109 4.24 3 109 99.63 39.03 25.9 3 106 66 43 2.54 6
E161 9.21 3 109 4.22 3 109 91.63 43.33 18.7 3 106 182 81 9.74 10
E170 9.10 3 109 4.09 3 109 1063 39.63 28.1 3 106 188 98 6.69 24
E172 9.67 3 109 3.53 3 109 99.53 30.23 28.3 3 106 41 26 1.45 9
The mutation rate was calculated by dividing the total number of somatic mutations by the total number of callable nucleotide positions ($153 in tumor
and $83 in matched normal samples).
Figure 2. Mutation profile of somatic mutations in the exomes of endometrial cancer. The frequency
of six classes of mutations is shown for all mutations in the exomes, nonsilent coding mutations, and
silent mutations, respectively.
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screen. As shown in Figure 4A, overexpression of wild-type ERBB3
significantly increased cell survival, consistent with its proposed
role as an oncogene, but the P590Lmutation showed no difference
relative to the wild-type, suggesting that this mutation is not
functional, albeit in terms of survival in the Ba/F3 assay. Compared
with controls, overexpression of wild-type AKTIP and INHBA sig-
nificantly reduced cell survival, consistent with their potential roles
as tumor suppressors. Interestingly, their corresponding mutations
(Q281K in AKITP and R310Q in INHBA) significantly increased the
Ba/F3 survival compared to the wild-type constructs (P < 0.05),
suggesting a critical inactivating effect of these mutations and
strongly supporting AKTIP and INHBA as bona fide tumor sup-
pressors. In contrast, upon overexpression, wild-type or mutants of
the GRM8, PHKA2, and WNT11 genes which scored positive in
the shRNA screen showed no significant effect on survival of Ba/F3,
suggesting that the effects of these genes may be dosage-in-
dependent and are not evident in the presence of thewild-type gene
inBa/F3 cells. Concordantwith the lack of effect in theBa/F3 shRNA
screen, there was no significant change in Ba/F3 survival with
overexpression of the remaining 11 genes or their mutants (Fig. 4B).
Effect of candidate driver cancer genes by siRNA knockdown
in endometrial cancer cell lines
To extend our observations in Ba/F3 cells to human endometrial
cancer cells, we introduced siRNAs targeting the 12 candidate
driver cancer genes into four human endometrial cancer cell lines
and assessed effects on cell viability. We included an siRNA tar-
geting the established PTEN tumor-suppressor gene to validate the
approach. As shown in Figure 5 and
Supplemental Figure 4, decreased PTEN
protein and increased AKT phosphory-
lation was accompanied by significant
increased cell viability in PTEN siRNA-
transfected cells carrying awild-type PTEN
gene and expressing PTEN protein, but not
in PTEN protein-negative cell lines, sup-
porting the utility of the approach. Im-
portantly, KLE, in which all genes assessed
were wild-type, exhibited the same re-
sponses to the corresponding shRNA as Ba/
F3 except for IGFBP3 siRNA (Fig. 5B). The
responses of EFE184 (all genes tested
are wild-type except ARID1A with un-
detectable protein expression), SK-UT-2
(ARID1A is mutated with detectable
protein; mutation status of others is un-
known), and SNG-II (ARID1A is mu-
tated with undetectable protein; the mu-
tation status of the others is unknown)
were more variable (Supplemental Fig. 4).
ARID1A siRNA only demonstrated altered
viability of KLE and SK-UT-2 where the
ARID1A protein is expressed (Fig. 5B;
Supplemental Fig. 4). Importantly, AKTIP
siRNA significantly increased viability in
all cell lines, consistent with its potential
tumor-suppressor role suggested in the
Ba/F3 system. The siRNAs for WNT11
and INHBA increased viability in three
cell lines, whereas IGFBP3 siRNA in-
creased cell viability in two cell lines. In
contrast, ERBB3 and RPS6KC1 siRNAs inhibited cell viability in all
cell lines at least at one time point. siRNAs targeting NOS1AP,
PHKG1, and C1orf198, which had no effect in Ba/F3 survival, did
not alter cell viability in all of the endometrial cell lines we ex-
amined, providing additional support for the validity of the Ba/F3
model and the pipeline of characterization of mutations. Collec-
tively, the effect of silencing candidate driver genes in endometrial
cancer cell lines largely recapitulated the results obtained in Ba/F3
cells.
Regulation of PI3K pathway activation by ARID1A
ARID1A (AT-rich interactive domain 1A; also known as BAF250) is
a key member of the SWI/SNF chromatin-modeling complex, and
the gene has recently been reported to be frequently mutated in
a wide variety of cancer types (Jones et al. 2010; Wiegand et al.
2010, 2011; Guan et al. 2011b; Gui et al. 2011; Wang et al. 2011;
Mamo et al. 2012). While previous studies and our present results
suggest its potential role as a tumor suppressor, the molecular
mechanism underlying its functional role in cancer is largely un-
known. To explore howARID1A contributes to the pathogenesis of
endometrial cancer, we first resequenced this gene in the same
cohort of tumor samples (n = 222) as in our previous study (Cheung
et al. 2011) and observed a (nonsilent) mutation frequency of
41.6% (Fig. 6A; Supplemental Fig. 5). Strikingly,ARID1Amutations
co-occur withmutations in PTEN (Fisher exact test, P < 1.23 105,
Bonferroni corrected P < 1.0 3 104) and PIK3CA (P < 2.3 3 103,
Bonferroni corrected P < 1.8 3 102) (Fig. 6A; Supplemental Table
5), as well as with overall PI3K pathway aberration (P < 1.13 103,
Figure 3. Novel candidate driver cancer genes identified by shRNA screening in Ba/F3 viability assay.
(A) Ba/F3 cells were transfected with short-hairpin RNAs (shRNA) targeting indicated genes. Empty
vector (pGIPZ) and nonspecific shRNA served as the control. Cells were cultured without IL-3 for 4 wk
and harvested for viability assay. Cell viability relative to Ba/F3 parental cells was shown. (*) P < 0.05,
compared with Ba/F3 parental control. (B) Whole cell lysates were also collected for Western blotting
with indicated antibodies, and ERK2 was used as the loading control.
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Bonferroni corrected P < 8.6 3 103). Since coordinate PI3K
pathway mutations are common in endometrial cancer relative to
other cancer lineages, the concordance of aberrations in the PI3K
pathway and ARID1A could represent coordinate targeting of the
PI3K pathway or amutually exclusive function for ARID1A and the
PI3K pathway. We thus examined the effect of ARID1Amutations
on protein and phosphoprotein levels of coremembers in the PI3K
pathway using reverse-phase protein arrays and found that the
phosphorylation of several downstream targets (PDK1, AKT, GSK3,
TSC2, p70S6K, and ACC) are significantly up-regulated in tumors
with ARID1Amutations (two-sided t-test, P < 0.05, FDR < 0.1; Fig.
6B). Since (1) PTEN loss has a dominant effect on the activation of
the PI3K pathway (Hollander et al. 2011) and (2)ARID1A shows co-
mutation patterns with PTEN and PIK3CA, we then focused on
a subset of tumor samples in which both PTEN and PIK3CA genes
were wild-type, and also PTEN expression was retained (n = 47).
Strikingly, in these samples, phosphorylation of AKTpS473 and
p70S6KpS371, two key PI3K pathway proteins, remained signifi-
cantly up-regulated in ARID1A-mutated samples (Fig. 6C) as com-
pared with samples where ARID1A, PTEN, and PIK3CA are wild-
type, indicating that the activation of PI3K pathway by ARID1A
mutations is not due to co-occurrence of ARID1A mutations with
aberrations in PTEN or PIK3CA.
We determined whether ARID1A regulated PI3K pathway
activity in endometrial cancer cell lines. Consistent with RPPA
analysis from the large endometrial cancer sample cohort, knock-
down of ARID1A significantly elevated AKT phosphorylation
levels in three cell lines (KLE, ESS1, and
MFE280) expressing wild-type ARID1A
(Fig. 6D). In contrast, up-regulation of
AKT phosphorylation was not observed
in the EFE184 cell line in which ARID1A
protein is not present (Fig. 6D). These
results are consistent with inhibition of
the PI3K pathway contributing to the
tumor-suppressor activity of ARID1A.
Discussion
Our study represents the first unbiased
view of somatic mutations in endome-
trial cancer, which strongly complements
previous gene- and pathway-focused stud-
ies. More importantly, our results provide
substantial functional evidence for a di-
versity of novel candidate drivers, sug-
gesting key insights into the pathogenesis
of endometrial cancer with implications
for the development of targeted therapy.
Next-generation sequencing tech-
nology has facilitated characterization of
the full spectrum of aberrations in cancer
genomes in a cost-effective and timely
manner (Mardis 2011). However, there is
still a great gap between creating a catalog
of mutations and alterations and identi-
fying a short list of ‘‘actionable’’ elements
(Chin et al. 2011). Here we developed
a systems-biology approach to filling
this gap: We combined computation-
prediction-based prioritization with func-
tional screening in a highly sensitive cell
viability assay. This approach allows the identification of a large
number of candidate driver cancer genes in an efficient way. Fo-
cusing on a candidate driver gene of high interest, we further ex-
amined the underlying molecular mechanisms through an in-
tegrative analysis of mutation profile and protein expression on a
large, well-characterized sample set and ‘‘hypothesis-driven’’ func-
tional studies in endometrial cancer cell lines. These methods and
the related experimental systems can be readily applied to other
cancer types.
Through the combination of gene silencing and over-
expression strategies in Ba/F3 and endometrial cancer cell lines, we
revealed 12 potential driver cancer genes in endometrial cancer.
Among these genes, ARID1A has attracted wide interest recently.
Frequent mutations throughout the gene sequence including
multiple truncation mutations have been reported in ovarian
(Jones et al. 2010; Wiegand et al. 2010), gynecological (Guan et al.
2011b), bladder (Gui et al. 2011), gastric (Wang et al. 2011), breast
(Mamo et al. 2012), and endometrial cancers (Guan et al. 2011a;
Wiegand et al. 2011), suggesting a role as a tumor suppressor.
ARID1A encodes BAF250a, a nuclear protein and a key component
of the SWI/SNF chromatin-remodeling complex that functions as
a regulator of gene expression and chromatin dynamics (Wu et al.
2009). However, to date, themechanisms by which loss of ARID1A
function contributes to cancer pathophysiology remains poorly
understood. ARID1A has been suggested to suppress cell prolifer-
ation of ovarian and endometrial cancer cell lines through physi-
cally interacting with p53 to coordinately regulate the transcription
Figure 4. Candidate driver cancer genes confirmed by overexpression of wild-type genes or mutants
in Ba/F3 viability assay. Ba/F3 cells were transfected with wild-type (WT) or corresponding mutant(s)
(mutation sites indicated) of (A) six positive genes in the shRNA screen and (B) 11 genes inactive in the
screen. Cells transfected with shRNA were included in the assay as reference. pGIPZ vector is the empty
vector carrying shRNA while LacZ corresponds to b-galactosidase in the pLenti6.3 vector. Cells were
cultured without IL-3 for 4 wk and harvested for viability assay. Cell viability relative to Ba/F3 parental
cells was shown. (*) P < 0.05, compared with Ba/F3 parental control. (#) A significant difference in cell
viability between WT and mutant-transfected cells (P < 0.05).
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of cell cycle–related genes (Guan et al. 2011b), linking its function
to nuclear localization. Here we not only confirmed a high muta-
tion frequency in a large cohort of endometrial tumors, but also for
the first time, demonstrated that ARID1A can regulate PI3K path-
way activity, consistent with inhibition of the PI3K pathway
contributing to ARID1A tumor-suppressor activity. Since the PI3K
pathway represents a promising target for therapy (Hennessy et al.
2005), these results have direct implications for clinical trans-
lation. At present, it remains unclear which molecules in the
pathway are targeted by ARID1A, and further studies are required
to elucidate mechanistic details.
Among the other candidate tumor suppressors identified,
AKTIP, INHBA, and WNT11 appear to be the most promising
ones. AKTIP and INHBA are particularly likely to represent tumor
suppressors because knockdown and overexpression demon-
strated opposite effects in Ba/F3, and, critically, patient-derived
mutations abrogated the effects of the wild-type expression
construct (Figs. 3, 4). AKTIP was first identified as an AKT bind-
ing partner (Remy and Michnick 2004). Exogenous over-
expression of AKTIP enhanced AKT phosphorylation, but this
activation induced apoptosis for unknown reasons (Remy and
Michnick 2004). Based on data from the Cancer Genome Atlas,
homologous deletion of AKTIP occurs in multiple cancer line-
ages including breast (2%), ovary (0.9%), and prostate (1%),
consistent with a tumor-suppressor role. However, the func-
tional role of AKTIP could be tumor type-specific, since it has
been proposed as a putative oncoprotein in cervical cancer
but a tumor suppressor in ovarian cancer (Cinghu et al. 2011;
Notaridou et al. 2011). INHBA encodes inhibin beta A, a subunit
of both the activin and inhibin receptors of the transforming
growth factor (TGF-beta) superfamily (Risbridger et al. 2001).
Inhibin beta A, like TGF-beta, can inhibit or stimulate cell
growth dependent on the cellular con-
text. For example, INHBA substantially
inhibited tumor growth and angiogenesis
in in vivo gastric cancer and neuroblas-
toma models (Schramm et al. 2005;
Kaneda et al. 2011). Meanwhile, INHBA
mRNA was up-regulated in lung cancer
and may result in the promotion of cell
proliferation (Seder et al. 2009). In endo-
metrial cancer cell lines, the role of
INHBA is controversial (Di Simone et al.
2002; Tanaka et al. 2003). It is possible
that the contribution of INHBA to the
tumorigenesis is determined by the rela-
tive expression levels of other receptor
subunits and their interacting partners.
WNT11 is a key member of the Wingless-
type (Wnt) signaling pathway whose
deregulation has been implicated in endo-
metrioid endometrial tumors as evidence
by beta-catenin mutations and aberrant
nuclear accumulation (Ikeda et al. 2000;
Moreno-Bueno et al. 2002). The canoni-
cal Wnt cascade is mediated by nuclear
beta-catenin binding to T-cell factor tran-
scription factors to activate genes relevant
to tumorigenesis, while noncanonical
Wnt signaling is beta-catenin independent
(Bejsovec 2005). Interestingly, WNT11 is
down-regulated in hepatocellular carci-
noma, and it can modulate both canonical and noncanonical Wnt
pathways to execute its tumor-suppressor actions (Toyama et al.
2010). Thus, the role of WNT11 in Wnt signaling in endometrial
cancer warrants further investigation.
ERBB3 and RPS6KC1 are potential oncogenes identified in
our study. ERBB3 (HER3) belongs to the epidermal growth factor
receptor family and has been implicated in cancer, previously.
ERBB2, a partner of ERBB3, as well as ERBB3 itself is often am-
plified and overexpressed in breast, ovarian, prostate, and lung
cancers (for review, see Sithanandam and Anderson 2008).
Overexpression of ERBB3 promotes tumorigenesis through mul-
tiple mechanisms including cell cycle progression, stimulation of
cell migration, and invasion primarily via activation of the PI3K
pathway (Sithanandam and Anderson 2008). ERBB3 is highly
expressed in endometrial cancer, but the functional role remains
unclear (Srinivasan et al. 1999; Ejskjaer et al. 2007). RPS6KC1
(encoding ribosomal protein S6 kinase polypeptide 1) is another
potential oncogene. RPS6KC1 mutations have been previously
found in breast, ovary, and lung cancers (Davies et al. 2005;
Stephens et al. 2005; Cancer Genome Atlas Research Network
2011). Two independent studies show that RPS6KC1 does not have
kinase activity (Hayashi et al. 2002; Liu et al. 2005), but, instead,
likely functions as an adaptor molecule to recruit binding part-
ners (sphingosine kinase-1 and peroxiredoxin-3) to early endo-
somes (Hayashi et al. 2002; Liu et al. 2005). These trafficking
pathways within the endosomal system play a fundamental role
in regulating protein degradation, recycling, secretion, and
compartmentalization; and, indeed, defective vesicular traffick-
ing is a hallmark of malignant transformation (Mosesson et al.
2008).
Our study has several limitations. First, somatic alter-
ations in noncoding regions, genome rearrangements, and copy
Figure 5. Functional effect of candidate driver cancer genes by siRNA-mediated gene silencing in KLE
endometrial cancer cell line. KLE cells were transfected with siRNAs targeting the indicated genes.
Mock, risc-free siRNA, and nonspecific siRNA served as controls. (A) Efficacy of PTEN siRNA on AKT
phosphorylation was determined by Western blotting. Cells transfected with indicated siRNAs were
assayed for cell viability (B) 7 d or (C ) 5 d post-transfection. Cell viability relative to mock-transfected
cells was shown. (*) P < 0.05, compared with mock control.
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number variations would have been missed. Second, the num-
ber of samples sequenced is relatively small, thus sequencing
of additional samples will be necessary to establish a compre-
hensive genomic landscape for endometrial cancer. Finally,
additional functional and clinical studies will be required
before the insights from the genomic analysis can be trans-
lated into effective personalized therapy for endometrial
cancer.
Figure 6. Mutational and functional analysis of ARID1A on the activation of the PI3K pathway. (A) Co-mutation patterns of ARID1A and key genes
related to the PI3K pathway. (Upper panel) Mutation diagram in the full set of endometrial tumor samples (n = 222). Each column represents a tumor,
and each row corresponds to a single gene. (Lower panel) Mutation or co-mutation frequencies are expressed as a percentage of all the samples, and the
co-mutation frequencies from random expectation are shown in parentheses for comparison. (Dark red) Genes with statistically significant co-mu-
tations, accompanied with Bonferroni-corrected P-values. (B) The functional effect of ARID1Amutation on protein expression of the PI3K pathway. Each
arrow represents a protein marker with significant differential expression between ARID1A wild-type and mutated samples: (red arrows) phosphory-
lated proteins and (green arrows) total proteins with P < 0.05 (two-sided t-test, FDR < 0.1); (orange arrows) phosphorylated proteins with marginal
significance P < 0.07 (FDR < 0.13). (Solid red) Activated genes; (solid gray) genes without available protein expression data. (C ) The functional effect of
ARID1A mutation on the phosphorylation of AKT and p70S6K in tumor samples in which both PTEN and PIK3CA genes are wild-type, and also PTEN
expression is retained (n = 47). P-values were calculated based on a two-sided t-test. (Boxes) The distribution of individual values from the lower 25th
percentile to the upper 75th percentile; (solid line in the middle) median values; (lower and upper whisker) fifth and 95th percentiles; (small circles)
outlier data points. (D) Four endometrial cancer cell lines were transfected with 20 nM ARID1A siRNA or nonspecific siRNA and harvested after 72 h for
Western blotting with the indicated antibodies. Numerical values below each lane of the immunoblots represent the quantification of the relative
protein level by densitometry.
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Methods
Sample collection
All studies of 222 patients diagnosed at the University of TexasMD
Anderson Cancer Center (Houston, TX, USA) from 1998 to 2009
were approved by the Institutional Review Board. Tumor content
($80%), histological classification, grade, and stage were reviewed
by two independent pathologists. Genomic DNA from frozen tu-
mor resections was extracted by the MD Anderson Bioextraction
core using the QIAampDNAMini Kit (QIAGEN); normal DNAwas
extracted from peripheral blood leukocytes using the QIAamp
Blood kit (QIAGEN).
Exome sequencing and detection of somatic alterations
Whole-exome libraries (captured by Agilent SureSelect All Exon
Kit) were constructed and sequenced on a SOLiD V3.0 Genome
Analyzer using 50-nt single reads. Sequencing reads were pro-
cessed, mapped to the human genome (hg19), and analyzed using
Bioscope (version 1.21) combined with in-house scripts. Supple-
mental Figure 1 shows the overall computational pipeline for
detecting somatic mutations. Mutation validation was performed
by Sequenom MassARRAY genotyping, and whole-gene resequenc-
ing on the large sample cohort was performed by Sanger sequencing.
A complete description is provided in the Supplemental Methods.
Mutational analysis
Mutation data of ARID1A in 222 endometrial tumors were
obtained as previously described (Cheung et al. 2011). A two-sided
Fisher exact test was used to assess whether (nonsilent) mutations
inARID1A tend to co-occur withmutations in other genes (or PI3K
pathway aberrations) in the tumor samples. PI3K pathway aber-
rations were defined as PTEN loss or mutations in any pathway
genes (including PTEN, PIK3CA, PIK3R1, PIK3R2, and AKT1). A
Bonferroni correction was used to control multiple testing.
RPPA data analysis
To examine the effect of ARID1Amutations on the PI3K pathway,
high-throughput RPPA data for 24 PI3K-pathway-related proteins
in the 222 samples were obtained from our previous study
(Cheung et al. 2011). RPPA data were processed and normalized as
previously described (Park et al. 2010). A two-sided t-test was used
to test whether the expression of a given protein in ARID1A wild-
type samples was significantly different from that in ARID1A
mutated samples, and a false discovery rate (Benjamini and
Hochberg 1995) was used to control multiple testing.
Bioinformatics analysis
Pathway enrichment analysis was performed with Ingenuity
Pathways Analysis (IPA) (version 8.0). The status of PTEN was de-
termined as in our previous study (Cheung et al. 2011). A two-sided
Fisher exact test was used to assess whether ARID1A mutations
were correlated with the status of PTEN (loss or retained). To select
mutated genes for shRNA studies, functional effects of somatic
mutations were predicted with two programs: (1) CHASM (Carter
et al. 2010), mutations with FDR < 30% were selected; (2)
MutationAssessor (Reva et al. 2011), mutations with high func-
tional effect were selected.
Ba/F3 viability assays
The interleukin-3 (IL-3)–dependent prolymphoid cell line Ba/F3
was maintained in RPMI1640 medium containing 10% fetal bo-
vine serum supplemented with 5 ng/mL IL-3 at 37°C in a 5% CO2
atmosphere. Constructs containing wild-type genes or their cor-
responding mutants cloned into pLenti6.3 (Invitrogen) and
shRNAs in pGIPZ vector (Open Biosystems) were transfected into
Ba/F3 cells using the Neon electroporation system according to the
manufacturer’s instructions (Invitrogen). At 96 h post-transfection,
the cells were resuspended in medium without IL-3. Cells (53 103)
were plated in 96-well plates and cultured for 4 wk. Cell viability
was evaluated using Cell Titer Blue (Promega) for mitochondrial
dehydrogenase activity. Statistical analysis was performed using
ANOVA followed by Tukey’s post hoc test (GraphPad Software).
P < 0.05 was considered statistically significant.
siRNA transfection in endometrial cancer cell lines
Endometrial cell lines EFE-184, ESS-1, andMFE280were purchased
from DSMZ-German Collection of Microorganisms and Cell Cul-
tures (Braunschweig, Germany). KLE was provided by Dr. Russell
Broaddus (MDAndersonCancerCenter, Houston, TX), and SK-UT-2
was kindly provided by Dr. Bo R. Rueda (Massachusetts General
Hospital, Boston). All cell lines were cultured in media according
to the suppliers’ instructions at 37°C in a 5% CO2 atmosphere.
Cells were transfected with 20 nM siRNAs (Dharmacon) using
Lipofectamine RNAiMAX reagent (Invitrogen) according to
the manufacturers’ instructions. The cells were harvested at
time points as indicated in the figure legends and processed for
either cell viability assay usingCell Titer Blue (Promega) orWestern
blot analysis.
Western blotting
Whole-cell lysates were extractedwith RIPA lysis buffer (1%NP-40,
5 mM EDTA, 1 mM sodium orthovanadate, 1% phenyl-
methylsulphonyl fluoride, and complete protease inhibitor
cocktail). The protein concentrations were determined with DC
Protein Assay Reagent (Bio-Rad Laboratories). Cell lysates (25 mg)
were loaded onto SDS/PAGE and transferred to a Hybond-ECL ni-
trocellulose membrane (Amersham Biosciences). The membrane
was blocked with 5% nonfat milk and incubated with primary
antibody overnight at 4°C. Protein expression was visualized with
an ECL plus kit (Amersham Biosciences).
Data access
The sequencing data from this study can be accessed at the Euro-
pean Genome-phenome Archive (EGA) (http://www.ebi.ac.uk/
ega/) under accession number EGAS00001000318.
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